- Conditions
- Obesity, Overweight
- Interventions
- NNC0174-1213 A, Cagrilintide B, Placebo A (NNC0174 1213 A)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- San Antonio, Texas • Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Overweight, Obesity
- Interventions
- Cagrisema, Placebo CagriSema
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Pelham, Alabama • Hawthorne, California + 22 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- CagriSema, Placebo CagriSema
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 64 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 21
- States / cities
- Little Rock, Arkansas • San Diego, California • Spring Valley, California + 16 more
- Conditions
- Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
- Interventions
- CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 19
- States / cities
- La Mesa, California • San Diego, California • Miami, Florida + 14 more
- Conditions
- Obesity
- Interventions
- CagriSema (cagrilintide B and semaglutide I), CagriSema A
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Obesity
- Interventions
- CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 46
- States / cities
- Costa Mesa, California • San Diego, California • Walnut Creek, California + 41 more
- Conditions
- Alcohol-related Liver Disease
- Interventions
- NNC0194-0499, Semaglutide, NNC0194-0499 placebo, Semaglutide placebo (Group A), Cagrilintide + semaglutide, Cagrilintide, Cagrilintide placebo, Semaglutide placebo (Group B)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 29
- States / cities
- Chandler, Arizona • Tucson, Arizona • Lancaster, California + 23 more
- Conditions
- Overweight, Obesity
- Interventions
- Cagrilintide B, Cagrilintide D
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Obesity
- Interventions
- CagriSema (Cagrilintide B + semaglutide I), Low Energy Diet
- Drug · Behavioral
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Baton Rouge, Louisiana
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 21
- States / cities
- New Haven, Connecticut • Boynton Beach, Florida • Jacksonville, Florida + 18 more